New Drug's stomach acid effects tested in healthy volunteers
NCT ID NCT07446881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 study tested how a single dose of ADV7103 affects stomach acid levels in 12 healthy adults, both with and without food. The goal was to understand how the drug behaves in the stomach. Results may help guide future dosing for people with distal renal tubular acidosis, a kidney condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADV7103 (Sibnayal)
- What this could lead to
- If successful, this could help understand how ADV7103 works in the stomach, potentially improving dosing for kidney disease treatment.
- What could go wrong
- This is a very early Phase 1 study in only 12 healthy people, not patients. Results may not predict real-world effects or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DISTAL RENAL TUBLULAR ACIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center Eugène Marquis, Laboratoire de Biologie
Rennes, 35042, France